UB Paderborn / Katalog / Suche / in CDI

The vaccination registry of the local health company (ASL) Roma 4

European journal of public health, 2020-09, Vol.30 (Supplement_5)

2020

Volltextzugriff (PDF)

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

Nature communications, 2023-09, Vol.14 (1), p.5529-5529, Article 5529

2023

Volltextzugriff (PDF)

Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature

Frontiers in pharmacology, 2022-06, Vol.13, p.867907-867907

2022

Volltextzugriff (PDF)

Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Cell death & disease, 2022-04, Vol.13 (4), p.398-398, Article 398

2022

Volltextzugriff (PDF)

The role of integrative and complementary medicine in the management of breast cancer patients on behalf of the Integrative Medicine Research Group (IMRG)

European review for medical and pharmacological sciences, 2022-02, Vol.26 (3), p.947

2022

Volltextzugriff (PDF)

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Cell death & disease, 2024-01, Vol.15 (1), p.68-68, Article 68

2024

Volltextzugriff (PDF)

2260P Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels

Annals of oncology, 2023-10, Vol.34, p.S1162-S1162

2023

Volltextzugriff (PDF)

Endocannabinoid system expression in ovarian epithelial tumors according to the dualistic model of ovarian carcinogenesis

European review for medical and pharmacological sciences, 2021-07, Vol.25 (14), p.4678

2021

Volltextzugriff (PDF)

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Cell death & disease, 2023-08, Vol.14 (8), p.572-572, Article 572

2023

Volltextzugriff (PDF)

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Cell death & disease, 2023-08, Vol.14 (8), p.521-521, Article 521

2023

Volltextzugriff (PDF)

13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels

Annals of oncology, 2022-09, Vol.33, p.S550

2022

Volltextzugriff (PDF)

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity

Frontiers in cardiovascular medicine, 2024-05, Vol.11, p.1289663

2024

Volltextzugriff (PDF)

2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

Annals of oncology, 2023-10, Vol.34, p.S1181-S1181

2023

Volltextzugriff (PDF)

2296P SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways

Annals of oncology, 2023-10, Vol.34, p.S1175-S1175

2023

Volltextzugriff (PDF)

6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways

Annals of oncology, 2021-09, Vol.32, p.S362-S362

2021

Volltextzugriff (PDF)

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Cell death & disease, 2022-05, Vol.13 (5), p.445-445, Article 445

2022

Volltextzugriff (PDF)

2244P Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models

Annals of oncology, 2023-10, Vol.34, p.S1155-S1156

2023

Volltextzugriff (PDF)

14P Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction

Annals of oncology, 2022-09, Vol.33, p.S550

2022

Volltextzugriff (PDF)

Treatment options after regorafenib failure in metastatic colorectal cancer

European review for medical and pharmacological sciences, 2021-07, Vol.25 (13), p.4441

2021

Volltextzugriff (PDF)

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways

European heart journal, 2023-11, Vol.44 (Supplement_2)

2023

Volltextzugriff (PDF)

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

European heart journal, 2022-10, Vol.43 (Supplement_2)

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

The vaccination registry of the local health company (ASL) Roma 4

Fasting mimicking diet in mice delays cancer growth and reduces immunotherapy-associated cardiovascular and systemic side effects

Improved Survival and Quality of Life Through an Integrative, Multidisciplinary Oncological Approach: Pathophysiological Analysis of Four Clinical Cancer Cases and Review of the Literature

Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

The role of integrative and complementary medicine in the management of breast cancer patients on behalf of the Integrative Medicine Research Group (IMRG)

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

2260P Berberine associated to SGLT-2i exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-blocking agent trastuzumab through pAMPK activation and reduction in Interleukin-6 levels

Endocannabinoid system expression in ovarian epithelial tumors according to the dualistic model of ovarian carcinogenesis

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

13P Berberine associated to SGLT2i dapagliflozin synergistically reduces cardiac cell apoptosis during exposure to trastuzumab through induction of pAMPK and reduction of NLRP3 inflammasome, IL-6, methylglyoxal and leukotrienes-B4 levels

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity

2312P SGLT2i dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

2296P SGLT2 i dapagliflozin reduces NF-kB expression in heart and kidneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways

6MO PCSK9 inhibitor evolocumab reduces cardiotoxicity and inflammation induced by doxorubicin-trastuzumab sequential treatment through MyD88/NF-kB/mTORC1 pathways

Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy

2244P Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models

14P Sacubitril-valsartan increases pAMPK and reduces NLRP3, MyD88, interleukin-6 and galectin-3 in short-term doxorubicin-treated mice improving longitudinal strain and ejection fraction

Treatment options after regorafenib failure in metastatic colorectal cancer

SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity

The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) improves ejection fraction and longitudinal strain in mice treated with doxorubicin through NLRP3

TheSGLT-2 inhibitor dapagliflozin ehnanced the anticancer activities and exerts cardioprotective effects during exposure to ipilimumab through NLRP3 inflammasome and pro-fibrotic cytokines

Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways

Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue

Suchergebnisse filtern